Longeveron Inc. (Class A) (LGVN) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 31.2 (OVERSOLD (<32))
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While LGVN currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.90) and Max Pain ($1.84) forces dealer call-delta covering toward $12.92.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Longeveron Inc. (Class A) (LGVN) slipped -1.68% to $1.75, trading at 4% of its 52-week range ($1.31 – $12.3). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (the “Company”) (NASDAQ: LGVN), today announced that the Company has retained Lucid Capital Markets, LLC as the Company’s financial advisor to explore potential st
Important Secondary Clinical Outcome Endpoint MACE Achieved Statistical SignificanceELPIS II 2 Data in HLHS Selected for Late-Breaking Science Program Podium Presentation in the American Heart Association’s (AHA) 2026 Sc
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced updated results from ELPIS II
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics (NASDAQ:AARD) stock
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -49.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on LGVN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for LGVN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Longeveron Inc. (Class A) (LGVN) ranks #903 by composite RQD confidence (32/100, grade E) and #936 by equity capitalization ($5.6M). Within this direct 5-issuer industry benchmark cohort, LGVN leads on earnings valuation at N/A trailing P/E, while LGVN leads on capital efficiency and profitability with -35.0% ROIC and 67.0% gross margin. GELS currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with LGVN at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LGVN
ACTIVE
Longeveron Inc. (Class A) | E | 32/100 | — | 67.0% | -35.0% | -1.68% | $5.6M | Benchmark Subject |
| BGMS Bio Green Med Solution Inc. | D- | 40/100 | — | — | -35.0% | -9.79% | $5.5M | /bgms-vs-lgvn → |
| SCNX Scienture Holdings Inc. | D- | 42/100 | — | 76.8% | -35.0% | +2.65% | $5.7M | /scnx-vs-lgvn → |
| GELS Gelteq Limited | C- | 59/100 | — | — | — | +5.11% | $5.4M | /gels-vs-lgvn → |
| SKYE Skye Bioscience Inc. | D- | 36/100 | — | — | -35.0% | -13.82% | $5.8M | /skye-vs-lgvn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Longeveron Inc. (Class A) (LGVN) reported GAAP revenue of $1.2M (-49.9% vs. FY2024 revenue of $2.4M , and +69.1% cumulative change since FY2023) , GAAP net income of -$22.7M, operating cash flow of -$18.6M, and free cash flow of -$18.9M (-30.1% YoY). On the balance sheet, LGVN closed FY2025 with $10.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.2M | -$22.7M | -$18.6M | -$18.9M | $10.3M | — |
| FY2024 (FY) | 2024-12-31 | $2.4M | -$16.0M | -$13.9M | -$14.5M | $25.6M | — |
| FY2023 (FY) | 2023-12-31 | $709.0K | -$21.4M | -$19.0M | -$19.0M | — | — |
As of 2026-11-01, Longeveron Inc. (Class A) (NASDAQ: LGVN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.75 (-1.68% 1D, market cap $5.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LGVN ranks #903 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LGVN carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 67.0%, and ROIC of -35.0%. By comparison, BGMS (Bio Green Med Solution Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $5.5M) and SCNX (Scienture Holdings Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M). Among the 5-stock peer group, LGVN leads on earnings multiple (N/A) while LGVN leads on capital efficiency (-35.0% ROIC).
Per LGVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001721484), Longeveron Inc. (Class A) generated $1.2M in revenue (-49.9% YoY), -$22.7M in net income, and -$18.9M in free cash flow against $10.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
LGVN last traded at $1.75 (-1.68% on volume of 64,778 shares), positioning the stock -55.13% below its 50-day simple moving average ($3.90) and -73.64% below its 200-day simple moving average ($6.64). Across its 52-week range of $1.31 to $12.30, LGVN sits at the 4.0% percentile with a 14-day RSI of 31.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.53 to $1.97).
Why LGVN Stock slipped -1.68% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.